Literature DB >> 16778262

Effect of continuous positive airway pressure on ambulatory BP in patients with sleep apnea and hypertension: a placebo-controlled trial.

Francisco Campos-Rodriguez1, Antonio Grilo-Reina, Jose Perez-Ronchel, Mercedes Merino-Sanchez, Maria A Gonzalez-Benitez, Manuel Beltran-Robles, Carmen Almeida-Gonzalez.   

Abstract

BACKGROUND: Obstructive sleep apnea syndrome (OSAS) is an independent risk factor for arterial hypertension. Several controlled trials have investigated the effect of continuous positive airway pressure (CPAP) on BP in patients with OSAS, but its effect on hypertensive patients has not been analyzed specifically.
OBJECTIVE: To analyze the effect of CPAP on ambulatory BP in patients with OSAS and hypertension who were undergoing antihypertensive treatment. DESIGN AND PATIENTS: We conducted a parallel, randomized, placebo-controlled trial in 68 patients with OSAS and hypertension, who were receiving treatment with antihypertensive medication. Patients were randomly allocated to either therapeutic or subtherapeutic CPAP for 4 weeks. Ambulatory BP was registered at baseline and after treatment. Antihypertensive treatment was not changed during the study. Changes in BP were assessed on an intention-to-treat basis.
RESULTS: There were no baseline differences in the apnea-hypopnea index, comorbidities, or ambulatory BP between groups. Objective compliance with CPAP was similar in both the therapeutic and subtherapeutic groups (5.0 +/- 1.4 h/d vs 4.4 +/- 1.9 h/d, respectively; p = 0.13 [mean +/- SD]). There was a small and statistically nonsignificant decrease (- 0.3 +/- 6.3 mm Hg vs - 1.1 +/- 7.9 mm Hg; difference, - 0.8 mm Hg [95% confidence interval, - 2.7 to 4.3]; p = 0.65) in 24-h mean BP (24hMBP) in both subtherapeutic and therapeutic groups after 4 weeks of treatment. No significant changes in systolic, diastolic, daytime, or nighttime BP were observed. The normal circadian dipper pattern was restored in a higher proportion of patients in the therapeutic group compared to the subtherapeutic CPAP group, although differences were not significant (11 of 32 patients vs 3 of 25 patients; odds ratio, 3.84; 95% confidence interval, 0.82 to 20.30; p = 0.10). There was no correlation between the magnitude of change in 24hMBP and CPAP compliance, OSAS severity, or number of antihypertensive drugs used.
CONCLUSION: Four weeks of CPAP did not reduce BP in patients with OSAS and hypertension who were treated with antihypertensive medication, compared to placebo group.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16778262     DOI: 10.1378/chest.129.6.1459

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  53 in total

Review 1.  Resistant hypertension and sleep apnea: pathophysiologic insights and strategic management.

Authors:  Stephen K Williams; Joseph Ravenell; Girardin Jean-Louis; Ferdinand Zizi; James A Underberg; Samy I McFarlane; Gbenga Ogedegbe
Journal:  Curr Diab Rep       Date:  2011-02       Impact factor: 4.810

2.  Evaluation of sham-CPAP as a placebo in CPAP intervention studies.

Authors:  George W Rodway; Terri E Weaver; Cristina Mancini; Jacqueline Cater; Greg Maislin; Bethany Staley; Kathleen A Ferguson; Charles F P George; David A Schulman; Harly Greenberg; David M Rapoport; Joyce A Walsleben; Teofilo Lee-Chiong; Samuel T Kuna
Journal:  Sleep       Date:  2010-02       Impact factor: 5.849

Review 3.  Positive pressure therapy: a perspective on evidence-based outcomes and methods of application.

Authors:  Mark H Sanders; Josep M Montserrat; Ramon Farré; Rachel J Givelber
Journal:  Proc Am Thorac Soc       Date:  2008-02-15

4.  The impact of CPAP on cardiovascular biomarkers in minimally symptomatic patients with obstructive sleep apnea: a pilot feasibility randomized crossover trial.

Authors:  Vikram R Comondore; Rupi Cheema; Joel Fox; Arsalan Butt; G B John Mancini; John A Fleetham; C Frank Ryan; Sammy Chan; Najib T Ayas
Journal:  Lung       Date:  2008-09-16       Impact factor: 2.584

Review 5.  Obstructive sleep apnea and hypertension: mechanisms, evaluation, and management.

Authors:  John M Dopp; Kevin J Reichmuth; Barbara J Morgan
Journal:  Curr Hypertens Rep       Date:  2007-12       Impact factor: 5.369

6.  Variables affecting the change in systemic blood pressure in response to nasal CPAP in obstructive sleep apnea patients.

Authors:  Junaid Malik; Christopher L Drake; David W Hudgel
Journal:  Sleep Breath       Date:  2008-03       Impact factor: 2.816

7.  Effects of losartan and allopurinol on cardiorespiratory regulation in obstructive sleep apnoea.

Authors:  Barbara J Morgan; Mihaela Teodorescu; David F Pegelow; Emily R Jackson; Devin L Schneider; David T Plante; James P Gapinski; Scott J Hetzel; John M Dopp
Journal:  Exp Physiol       Date:  2018-06-08       Impact factor: 2.969

Review 8.  Obstructive sleep apnea, hypertension and cardiovascular diseases.

Authors:  C Gonzaga; A Bertolami; M Bertolami; C Amodeo; D Calhoun
Journal:  J Hum Hypertens       Date:  2015-03-12       Impact factor: 3.012

Review 9.  Pathophysiology of sleep apnea.

Authors:  Jerome A Dempsey; Sigrid C Veasey; Barbara J Morgan; Christopher P O'Donnell
Journal:  Physiol Rev       Date:  2010-01       Impact factor: 37.312

10.  Effects of nocturnal continuous positive airway pressure therapy in patients with resistant hypertension and obstructive sleep apnea.

Authors:  Tarek A Dernaika; Gary T Kinasewitz; Maroun M Tawk
Journal:  J Clin Sleep Med       Date:  2009-04-15       Impact factor: 4.062

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.